XFOR
NASDAQ · Biotechnology
X4 Pharmaceuticals Inc
$3.58
+0.08 (+2.29%)
Open$3.48
Previous Close$3.50
Day High$3.64
Day Low$3.48
52W High$4.83
52W Low$2.80
Volume—
Avg Volume1.28M
Market Cap347.01M
P/E Ratio—
EPS$-1.24
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+693.9% upside
Current
$3.58
$3.58
Target
$28.42
$28.42
$21.41
$28.42 avg
$38.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 80.47M | 38.69M | 57.05M |
| Net Income | -181,513,314 | -510,081,137 | 9.29M |
| Profit Margin | -225.6% | -1,391.4% | 16.3% |
| EBITDA | -196,198,387 | -479,400,827 | 17.50M |
| Free Cash Flow | — | — | 7.43M |
| Rev Growth | — | -5.2% | +3.4% |
| Debt/Equity | 0.41 | 3.41 | 0.94 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |